KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Onto Innovation (ONTO) Other Operating Expenses (2016 - 2026)

Onto Innovation has reported Other Operating Expenses over the past 17 years, most recently at $39.3 million for Q1 2026.

  • Quarterly results put Other Operating Expenses at $39.3 million for Q1 2026, up 10.8% from a year ago — trailing twelve months through Jan 2026 was $126.7 million (down 5.68% YoY), and the annual figure for FY2026 was $132.3 million, down 27.57%.
  • Other Operating Expenses for Q1 2026 was $39.3 million at Onto Innovation, up from $29.6 million in the prior quarter.
  • Over the last five years, Other Operating Expenses for ONTO hit a ceiling of $39.3 million in Q1 2026 and a floor of $28.2 million in Q1 2025.
  • Median Other Operating Expenses over the past 5 years was $30.4 million (2022), compared with a mean of $31.4 million.
  • Biggest five-year swings in Other Operating Expenses: increased 21.53% in 2024 and later decreased 14.71% in 2025.
  • Onto Innovation's Other Operating Expenses stood at $30.2 million in 2022, then increased by 6.86% to $32.3 million in 2023, then rose by 9.92% to $35.5 million in 2024, then decreased by 16.49% to $29.6 million in 2025, then skyrocketed by 32.68% to $39.3 million in 2026.
  • The last three reported values for Other Operating Expenses were $39.3 million (Q1 2026), $29.6 million (Q3 2025), and $29.6 million (Q2 2025) per Business Quant data.